Home › Targets › MET
MET (1 companies · 13 programs)
Companies with an active program directed at MET.
- CABOMETYX — Renal Cell Carcinoma Approved
- CABOMETYX — Hepatocellular Carcinoma Approved
- CABOMETYX — Differentiated Thyroid Cancer Approved
- CABOMETYX — Pancreatic Neuroendocrine Tumors Approved
- CABOMETYX — Extra-Pancreatic Neuroendocrine Tumors Approved
- zanzalintinib — Colorectal Cancer NDA Submitted
- zanzalintinib — Non-Clear Cell Renal Cell Carcinoma Phase 3
- zanzalintinib — Renal Cell Carcinoma Phase 3
- zanzalintinib — Neuroendocrine Tumors Phase 2
- zanzalintinib — Meningioma Phase 2
- zanzalintinib — Non-Small Cell Lung Cancer Phase 1
- zanzalintinib — Castration-Resistant Prostate Cancer Phase 2
- zanzalintinib — Bladder Cancer Phase 1
